Tag: CX 2021
More mixed results for DCBs in AV access maintenance as evidence...
Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...
Interventional News’ top 10 most popular stories for April 2021
Three of our top 10 stories of April 2021 highlight new data and ideas presented at this year's Charing Cross (CX) Symposium, Digital Edition...
“Radiation will be a thing of the past”: FORS in the...
Opening the Charing Cross (CX) 2021 Digital Edition (19–22 April, online), experts deliberated crucial controversies in the abdominal aortic space. Discussion emphasised the potential...
CX audience supports call to change agency recommendations regarding paclitaxel use...
Addressing representatives from the US Food and Drug Administration (FDA) and UK Medicines and Healthcare products Regulatory Agency (MHRA) directly, Thomas Zeller (Bad Krozingen,...
Two-year IN.PACT AV Access results presented at CX 2021
Medtronic recently announced the safety and effectiveness results through 24 months for the IN.PACT AV Access clinical study. The data, which were presented virtually...
CX to highlight impact of high-flow arteriovenous fistulas in Vascular Access...
Nicholas Inston (Queen Elizabeth Hospital Birmingham, Birmingham, UK) speaks to Vascular News ahead of this year’s Charing Cross Symposium (CX), which is being held online 19–22 April. In...
CX to host “vital” global discussion of paclitaxel controversy
Andrew Holden (Auckland City Hospital; University of Auckland, Auckland, New Zealand) speaks to Interventional News ahead of this year’s Charing Cross Symposium (CX), which...
